Atlas Trials

A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy

Clinical trial NCT07176702 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07176702
Sponsor
Shanghai Zhongshan Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic PDACHER2-positive Status
Start date
2025-09-30
Primary completion
2027-03-05
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.